Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis? - Wikidata - wikimedia - TriplyDB

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

http://www.wikidata.org/entity/Q42380186

about

Pauci-Immune Necrotizing and Crescentic Glomerulonephritis with Membranous Lupus Nephritis, Fifteen Years after Initial Diagnosis of Secondary Membranous Nephropathy Biologic agents in the treatment of glomerulonephritides.

P2860

Q36199241-88024616-11EC-4995-9590-81183334EBED Q38514894-ACADE784-CC32-4146-A5B0-16A44E519E1A

P2860

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

http://www.wikidata.org/entity/Q42380186

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

@en

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

@nl

type

label

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

@en

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

@nl

prefLabel

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

@en

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

@nl

P1433

Q42380186-06E138E1-DAB3-4DD7-9BA4-B3395127E44D

P1476

Q42380186-575B9922-A8F5-44CD-AE93-78FD11C0D9FB

P2093

Q42380186-983DE8B9-B74E-4F30-899A-540117D39596

P2860

Q42380186-050D34DB-034E-4865-AFFC-D627DA9F58C7

Q42380186-07AF455A-FD94-45D8-9295-E0CA373458F2

Q42380186-2450AEB8-7530-4CDD-A176-F0AE68EA5096

Q42380186-2452E49B-8E91-45B5-82C0-EA8093324A51

Q42380186-3F9D69EE-B9ED-4DAF-85C7-717051F7983C

Q42380186-477E62D6-A95B-4641-9773-2133F444EC01

Q42380186-4BB0DA84-344D-4779-B8AE-2A8ECC2EDB8F

Q42380186-4F36E465-9B9A-4805-BE1D-16D5E7A8432A

Q42380186-560AE323-5432-4FBA-B725-3B4DA703DB02

Q42380186-573649AB-7A20-4EB9-9497-B439A2450B95

P304

Q42380186-C643E019-2CCE-41BF-8D3B-29BAFEB59FE4

P31

Q42380186-5577BB38-F1E1-460B-9988-585DDC14978D

Q42380186-798487e7-7fe8-456b-b3c2-c0cd81352609

P356

Q42380186-267E724C-9CF4-491D-83E2-78F7CA8BFBB0

P433

Q42380186-CEF5FED2-E394-4038-891F-B6100CECCAB6

P478

Q42380186-E5D4D38A-E45D-43DB-801B-EED862AB2021

P50

Q42380186-0A4F83EC-DC1A-4598-911B-FFCF198BF4F1

P577

Q42380186-3F283539-19EE-40F8-A733-BAE1F2E150E3

P698

Q42380186-1F17F66D-68FF-408D-BF03-E52A10AD8D76

P932

Q42380186-A6BB5A1F-6272-416F-99A5-9383A7531948

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

@en

P2093

Charles D Pusey

http://www.w3.org/2001/XMLSchema#string

P2860

The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging

Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions.

A CD8+ T cell transcription signature predicts prognosis in autoimmune disease.

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis.

EULAR recommendations for the management of primary small and medium vessel vasculitis.

P304

641-644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.01270214

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24626431

http://www.w3.org/2001/XMLSchema#string

P932

3974343

http://www.w3.org/2001/XMLSchema#string